
Wanbury Q2 FY27 Revenue Up 14.3% YoY to ₹182.9 Cr
Wanbury Limited announced its financial results for the second quarter and half year ended September 30, 2026. For Q2 FY27, Revenue from Operations increased by 14.3% YoY to ₹182.9 crore and by 10.5% QoQ to ₹165.6 crore. EBITDA rose 57.9% QoQ to ₹26.2 crore, with EBITDA margin improving to 14.3%. PAT stood at ₹11.9 crore, a 21.7% decrease YoY, attributed to a provision for deferred tax liabilities. For H1 FY27, Revenue grew 7.8% YoY to ₹348.5 crore, with PAT at ₹15.1 crore. The company also incorporated Wanbury Skin Health Limited, an 82% subsidiary, impacting consolidated results. Key business updates include the resumption of Ketamine HCl API dispatches and expansion of the API portfolio with new product validations.
Key Highlights
- Q2 FY27 Revenue grew 14.3% YoY to ₹182.9 crore.
- EBITDA increased 57.9% QoQ to ₹26.2 crore.
- PAT declined 21.7% YoY to ₹11.9 crore due to tax provisions.
- H1 FY27 Revenue up 7.8% YoY to ₹348.5 crore.
- Resuming Ketamine HCl API dispatches and expanding API portfolio.
Price Impact
More from WANBURY